WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Emilio Paolo Alessandrino, Matteo Giovanni Della Porta, Andrea Bacigalupo, Maria Teresa Van Lint, Michele Falda, Francesco Onida, Massimo Bernardi, Anna Paola Lori, Alessandro Rambaldi, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Luca Malcovati, Cristiana Pascutto, Rosi Oneto, Renato Fanin, Alberto Bosi

Research output: Contribution to journalArticle

Abstract

We evaluated the impact of World Health Organization (WHO) classification and WHO classification-based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001). Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P

Original languageEnglish
Pages (from-to)895-902
Number of pages8
JournalBlood
Volume112
Issue number3
DOIs
Publication statusPublished - Aug 1 2008

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)'. Together they form a unique fingerprint.

  • Cite this